Effective diabetes care: a need for realistic targetsBMJ 2002; 324 doi: https://doi.org/10.1136/bmj.324.7353.1577 (Published 29 June 2002) Cite this as: BMJ 2002;324:1577
- Additional references
w1 Long-Term Intervention with Pravastatin in Ischemic disease (LIPID) Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Eng J Med 1998;339:1349-57.
w2 Yudkin JS. Therapeutic targets for type 2 diabetes post-UKPDS. J R Coll Phys Lond 2000;34:254-6.
w3 Akber M, Clegg C, Connor S, Casson IF. Outcome of insulin treatment in type 2 diabetic patients with secondary oral hypoglycaemic failure. Practical Diabetes 2000;18:10-2.
w4 Wolffenbuttel BHR, Gomis R, Squatrito S, Jones NP, Patwarhan RN. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabetic Med 2000;17:40-7.
w5 Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S. Netaglinide alone and in combination with metformin improves glycaemic control by reducing mealtime glucose level in type 2 diabetes. Diabetes Care 2000;23:1660-5.
w6 HOPE Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and the MICRO-HOPE study. Lancet 2000;355:253-9.
w7 Donnan PT, MacDonald TM, Morris AD for the DARTS.MEMO collaboration. Adherecne to prescribd oral hypoglycaemic medication in a population of patients with type 2 diabetes: a rerospective cohort study. Diabet Med 2002; 19:279-84.
w8 Turner RC, Millns H, Neil HAW, Stratton IM, Manley SE, Matthews DR, et al. Risk factors for coronary heart disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998;316:823-8.
w9 Ramsay LE, Haq IU, Jackson PR, Yeo WW, Pickin DM, Payne JN. Targeting lipid lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table. Lancet 1996;348:387-8.
w10 Jackson R. Updated New Zealand cardiovascular disease risk-benefit prediction guide. BMJ 2000;320:709-10.
w11 Yudkin JS. Which diabetic patients should be taking aspirin? BMJ 1995;311:641-2.
- Physical activity: a (mobile) call to actionBMJ January 28, 2020, 368 m316; DOI: https://doi.org/10.1136/bmj.m316
- Partha Kar: What will the 2020s hold for diabetes care?BMJ January 21, 2020, 368 m202; DOI: https://doi.org/10.1136/bmj.m202
- Diabetes technology: specialists are blocking access for some patients, say expertsBMJ October 17, 2019, 367 l6085; DOI: https://doi.org/10.1136/bmj.l6085
- Thousands more patients with type 1 diabetes are getting flash glucose devices, data showBMJ October 07, 2019, 367 l5895; DOI: https://doi.org/10.1136/bmj.l5895
- Obesity: raising price of sugary snacks may be more effective than soft drink taxBMJ September 05, 2019, 366 l5436; DOI: https://doi.org/10.1136/bmj.l5436
- Quality of Care of People With Type 2 Diabetes in Eight European Countries: Findings from the Guideline Adherence to Enhance Care (GUIDANCE) study
- Can the Retinal Screening Interval Be Safely Increased to 2 Years for Type 2 Diabetic Patients Without Retinopathy?
- Effect of the Look AHEAD Study Intervention on Medication Use and Related Cost to Treat Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes
- Combined Task Delegation, Computerized Decision Support, and Feedback Improve Cardiovascular Risk for Type 2 Diabetic Patients: A cluster randomized trial in primary care
- A cluster randomised controlled trial of the effect of a treatment algorithm for hypertension in patients with type 2 diabetes
- Polypharmacy as a Risk Factor in the Treatment of Type 2 Diabetes
- Physician, Organizational, and Patient Factors Associated With Suboptimal Blood Pressure Management in Type 2 Diabetic Patients in Primary Care
- Of Struldbruggs, sugar, and gatekeepers: a tale of our times
- Management of Uncontrolled Hypertension in a Nurse-Led Clinic Compared With Conventional Care for Patients with Type 2 Diabetes
- Insulin 70/30 Mix Plus Metformin Versus Triple Oral Therapy in the Treatment of Type 2 Diabetes After Failure of Two Oral Drugs: Efficacy, safety, and cost analysis
- Tough targets are necessary in effective diabetes care